ngd 94-1 and clozapine
ngd 94-1 has been researched along with clozapine in 5 studies
Compound Research Comparison
Studies (ngd 94-1) | Trials (ngd 94-1) | Recent Studies (post-2010) (ngd 94-1) | Studies (clozapine) | Trials (clozapine) | Recent Studies (post-2010) (clozapine) |
---|---|---|---|---|---|
15 | 0 | 4 | 9,691 | 747 | 3,148 |
Protein Interaction Comparison
Protein | Taxonomy | ngd 94-1 (IC50) | clozapine (IC50) |
---|---|---|---|
Adenylate cyclase type 1 | Rattus norvegicus (Norway rat) | 0.14 | |
Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.032 | |
Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 1.47 | |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.476 | |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.045 | |
Muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | 0.1233 | |
Muscarinic acetylcholine receptor M3 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M4 | Rattus norvegicus (Norway rat) | 0.1534 | |
5-hydroxytryptamine receptor 1A | Homo sapiens (human) | 0.15 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.031 | |
Muscarinic acetylcholine receptor M5 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.013 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.09 | |
Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | 0.14 | |
Muscarinic acetylcholine receptor M2 | Rattus norvegicus (Norway rat) | 0.1534 | |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.0096 | |
Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.2044 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0886 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.023 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0079 | |
D | Rattus norvegicus (Norway rat) | 1.066 | |
D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 1.2695 | |
Alpha-2B adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
D(2) dopamine receptor | Bos taurus (cattle) | 1.804 | |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.078 | |
D(1A) dopamine receptor | Homo sapiens (human) | 0.107 | |
D(4) dopamine receptor | Homo sapiens (human) | 0.0796 | |
Adenylate cyclase type 3 | Rattus norvegicus (Norway rat) | 0.14 | |
Alpha-2C adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
Alpha-2A adrenergic receptor | Rattus norvegicus (Norway rat) | 3.5772 | |
Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 1.47 | |
Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 5.7544 | |
Histamine H2 receptor | Homo sapiens (human) | 3.61 | |
Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.035 | |
D(1B) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
Adenylate cyclase type 2 | Rattus norvegicus (Norway rat) | 0.14 | |
Adenylate cyclase type 4 | Rattus norvegicus (Norway rat) | 0.14 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0658 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0658 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.373 | |
5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.587 | |
D(4) dopamine receptor | Rattus norvegicus (Norway rat) | 0.9312 | |
5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.587 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0338 | |
Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.023 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.546 | |
5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.028 | |
5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.028 | |
Histamine H1 receptor | Homo sapiens (human) | 0.0049 | |
D(3) dopamine receptor | Homo sapiens (human) | 0.354 | |
Adenylate cyclase type 8 | Rattus norvegicus (Norway rat) | 0.14 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.081 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0567 | |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.0171 | |
D(2) dopamine receptor | Mus musculus (house mouse) | 0.29 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.6759 | |
Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.028 | |
Adenylate cyclase type 6 | Rattus norvegicus (Norway rat) | 0.14 | |
Adenylate cyclase type 5 | Rattus norvegicus (Norway rat) | 0.14 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4162 | |
Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | 3.6 | |
Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 3.6 | |
5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 2 | |
Adenylyl cyclase 7 | Rattus norvegicus (Norway rat) | 0.14 | |
D | Bos taurus (cattle) | 4.09 |
Research
Studies (5)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (60.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Chen, X; Donovan, H; He, XS; Hoffman, DC; Hutchison, A; Jones-Hertzog, DK; Meade, R; Thurkauf, A; Wasley, JW; Woodruff, KH; Yuan, J | 1 |
Bristow, LJ; Hutson, PH; Rowley, M | 1 |
Hopkins, CR; Lindsley, CW | 1 |
Tallman, JF | 1 |
Gazi, L; Nozulak, J; Schoeffter, P; Sommer, B | 1 |
Reviews
2 review(s) available for ngd 94-1 and clozapine
Article | Year |
---|---|
Current and novel approaches to the drug treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Cholinergic Agonists; Disease Models, Animal; Dopamine Antagonists; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Humans; Mice; Mice, Transgenic; Nitric Oxide Synthase; Receptor, Serotonin, 5-HT2A; Receptors, AMPA; Receptors, Dopamine D2; Receptors, Dopamine D4; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotensin; Receptors, Serotonin; Schizophrenia; Serotonin Antagonists | 2001 |
Return of D
Topics: Animals; Drug Discovery; Humans; Ligands; Molecular Targeted Therapy; Neoplasms; Parkinson Disease; Receptors, Dopamine D4; Small Molecule Libraries; Substance-Related Disorders | 2017 |
Other Studies
3 other study(ies) available for ngd 94-1 and clozapine
Article | Year |
---|---|
2-Phenyl-4(5)-[[4-(pyrimidin-2-yl)piperazin-1-yl]methyl]imidazole. A highly selective antagonist at cloned human D4 receptors.
Topics: Antipsychotic Agents; Clozapine; Dopamine D2 Receptor Antagonists; Humans; Receptors, Dopamine D4 | 1997 |
NGD 94-1: a specific dopamine-4-receptor antagonist.
Topics: Animals; Antipsychotic Agents; Brain; Clozapine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Humans; Imidazoles; Pyrimidines; Radioligand Assay; Rats; Receptors, Dopamine D2; Receptors, Dopamine D4; Stereotyped Behavior; Tritium | 1998 |
NGD 94-1 as an agonist at human recombinant dopamine D4.4 receptors expressed in HEK293 cells.
Topics: Cells, Cultured; Clozapine; Dopamine Agonists; Humans; Imidazoles; Pyrimidines; Receptors, Dopamine D2; Receptors, Dopamine D4; Recombinant Proteins | 1999 |